These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 19592625)

  • 1. Potential of albiglutide, a long-acting GLP-1 receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing.
    Rosenstock J; Reusch J; Bush M; Yang F; Stewart M;
    Diabetes Care; 2009 Oct; 32(10):1880-6. PubMed ID: 19592625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus.
    Seino Y; Nakajima H; Miyahara H; Kurita T; Bush MA; Yang F; Stewart MW
    Curr Med Res Opin; 2009 Dec; 25(12):3049-57. PubMed ID: 19863477
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J; Stewart MW; Perkins CM; Cirkel DT; Ye J; Perry CR; Reinhardt RR; Bode BW
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of the once-weekly GLP-1 receptor agonist albiglutide versus sitagliptin in patients with type 2 diabetes and renal impairment: a randomized phase III study.
    Leiter LA; Carr MC; Stewart M; Jones-Leone A; Scott R; Yang F; Handelsman Y
    Diabetes Care; 2014 Oct; 37(10):2723-30. PubMed ID: 25048383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes.
    Trujillo JM; Nuffer W
    Ann Pharmacother; 2014 Nov; 48(11):1494-501. PubMed ID: 25136065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercise.
    Nauck MA; Stewart MW; Perkins C; Jones-Leone A; Yang F; Perry C; Reinhardt RR; Rendell M
    Diabetologia; 2016 Feb; 59(2):266-74. PubMed ID: 26577795
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical efficacy and safety of once-weekly glucagon-like peptide-1 agonists in development for treatment of type 2 diabetes mellitus in adults.
    Tzefos M; Harris K; Brackett A
    Ann Pharmacother; 2012 Jan; 46(1):68-78. PubMed ID: 22232377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial.
    Hernandez AF; Green JB; Janmohamed S; D'Agostino RB; Granger CB; Jones NP; Leiter LA; Rosenberg AE; Sigmon KN; Somerville MC; Thorpe KM; McMurray JJV; Del Prato S;
    Lancet; 2018 Oct; 392(10157):1519-1529. PubMed ID: 30291013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus.
    Seino Y; Inagaki N; Miyahara H; Okuda I; Bush M; Ye J; Holland MC; Johnson S; Lewis E; Nakajima H
    Curr Med Res Opin; 2014 Jun; 30(6):1095-106. PubMed ID: 24552155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5.
    Home PD; Shamanna P; Stewart M; Yang F; Miller M; Perry C; Carr MC
    Diabetes Obes Metab; 2015 Feb; 17(2):179-87. PubMed ID: 25406730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Albiglutide: A once-weekly glucagon-like peptide-1 receptor agonist for type 2 diabetes mellitus.
    Davis PN; Ndefo UA; Oliver A; Payton E
    Am J Health Syst Pharm; 2015 Jul; 72(13):1097-103. PubMed ID: 26092960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of albiglutide, a once-weekly glucagon-like peptide-1 receptor agonist, in patients with type 2 diabetes: A systematic review and meta-analysis.
    Kamrul-Hasan ABM; Dutta D; Nagendra L; Bhattacharya S; Singla R; Kalra S
    Medicine (Baltimore); 2024 Jun; 103(25):e38568. PubMed ID: 38905435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.
    Ratner R; Nauck M; Kapitza C; Asnaghi V; Boldrin M; Balena R
    Diabet Med; 2010 May; 27(5):556-62. PubMed ID: 20536952
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Albiglutide does not impair the counter-regulatory hormone response to hypoglycaemia: a randomized, double-blind, placebo-controlled, stepped glucose clamp study in subjects with type 2 diabetes mellitus.
    Hompesch M; Jones-Leone A; Carr MC; Matthews J; Zhi H; Young M; Morrow L; Reinhardt RR
    Diabetes Obes Metab; 2015 Jan; 17(1):82-90. PubMed ID: 25263215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glucagon-like peptide-1 receptor agonists in type 2 diabetes treatment: are they all the same?
    Gentilella R; Pechtner V; Corcos A; Consoli A
    Diabetes Metab Res Rev; 2019 Jan; 35(1):e3070. PubMed ID: 30156747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of an albiglutide liquid formulation compared with the lyophilized formulation: A 26-week randomized, double-blind, repeat-dose study in patients with type 2 diabetes mellitus.
    Shaddinger BC; Soffer J; Vlasakakis G; Shabbout M; Weston C; Nino A
    Diabetes Res Clin Pract; 2019 Jun; 152():125-134. PubMed ID: 31004676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.
    Okuda I; Wilson TH; Yue L; Nakajima H; Carr MC; Tsuboi M; Nino A; Seino Y
    Curr Med Res Opin; 2017 Mar; 33(3):431-438. PubMed ID: 27852119
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The fate of taspoglutide, a weekly GLP-1 receptor agonist, versus twice-daily exenatide for type 2 diabetes: the T-emerge 2 trial.
    Rosenstock J; Balas B; Charbonnel B; Bolli GB; Boldrin M; Ratner R; Balena R;
    Diabetes Care; 2013 Mar; 36(3):498-504. PubMed ID: 23139373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-Like Peptide-1 Receptor Agonists and Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus: Is It a Class Effect?
    Li Y; Rosenblit PD
    Curr Cardiol Rep; 2018 Sep; 20(11):113. PubMed ID: 30259238
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Albiglutide (Eperzan): a new once-weekly agonist of glucagon-like peptide-1 receptors].
    Scheen AJ
    Rev Med Liege; 2015 Apr; 70(4):207-14. PubMed ID: 26054173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.